NKGen Biotech, Inc. (NKGN)
OTCMKTS · Delayed Price · Currency is USD
0.1800
+0.0192 (11.94%)
Mar 28, 2025, 3:35 PM EST

NKGen Biotech Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21
Revenue
--0.080.43
Revenue Growth (YoY)
---81.92%-
Cost of Revenue
--0.020.03
Gross Profit
--0.060.4
Selling, General & Admin
18.1114.087.667.59
Research & Development
13.1915.6716.7514.67
Operating Expenses
31.329.7524.4122.26
Operating Income
-31.3-29.75-24.35-21.86
Interest Expense
-2.63-0.75-2.31-1.32
Other Non Operating Income (Expenses)
-45.65-48.180.08-0.08
EBT Excluding Unusual Items
-79.58-78.68-26.57-23.26
Merger & Restructuring Charges
--3.33--
Other Unusual Items
31.1-0.94-0.18-
Pretax Income
-48.47-82.95-26.75-23.26
Income Tax Expense
0.010.010.010.01
Net Income
-48.48-82.95-26.75-23.27
Net Income to Common
-48.48-82.95-26.75-23.27
Shares Outstanding (Basic)
2415614
Shares Outstanding (Diluted)
2415614
Shares Change (YoY)
103.97%142.70%-55.40%-
EPS (Basic)
-2.00-5.38-4.21-1.63
EPS (Diluted)
-2.00-5.38-4.21-1.63
Free Cash Flow
-20.87-21.95-22.66-19.95
Free Cash Flow Per Share
-0.86-1.42-3.56-1.40
Gross Margin
--76.62%92.96%
Operating Margin
---31618.18%-5131.69%
Profit Margin
---34745.46%-5461.27%
Free Cash Flow Margin
---29425.97%-4683.33%
EBITDA
-30.11-28.54-23.14-20.73
D&A For EBITDA
1.191.21.211.13
EBIT
-31.3-29.75-24.35-21.86
Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.